QALY time - Again!

... the never ending QALY discussion has been revisited by the BMJ in summer. Looks like with all the talk and difficulties associated around QALYs its time to bring some more economics back into the field and grow out a bit of the doctrin of biostatistics. In that regard a highly recommend the article from John FP Bridges "What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!" http://www.future-drugs.com/doi/abs/10.1586/14737167.6.1.19

No comments: